Adenosine and theophylline were linked covalently to oxidized stachyose to produce compounds too large to penetrate cell membranes. These compounds were used in two conscious and six open-chest anesthetized dogs to test the hypothesis that there is an adenosine receptor on the surface of the coronary myocyte. Intracoronary infusions of the adenosine derivative produced dose-dependent coronary vasodilation which was antagonized by theophylline; two types of theophylline derivative antagonized the coronary vasodilator) action of adenosine. Although these results show that both adenosine and theophylline exert their coronary effects at the surface of the smooth muscle cell, this evidence does not establish that they are competing for a common receptor.
THE VASODILATORY effect of adenosine has been known for over 40 years, 1 and its role as a physiological regulator of coronary vascular tone currently is under intense scrutiny. 2 This research effort has provided a substantial body of information describing the metabolism of adenosine by the cardiac cell, but little is known about how this nucleoside interacts with the coronary myocyte to cause it to relax. An "adenosine receptor" in the coronary vasculature has been proposed to explain the coronary vasoactivity of a number of purine nucleosides 3 and the antagonism of this effect by methylxanthines. 4 ' 5 Since most purine nucleosides 6 and methylxanthines' can penetrate cell membranes, it is not clear whether the putative adenosine receptor is located inside the coronary smooth muscle cell or is situated on its surface. This report describes the synthesis and coronary hemodynamic effects of derivatives of adenosine and theophylline covalently linked to an oligosaccharide. The molecular weights of these products, > 1,000 daltons, make it unlikely that they can penetrate into coronary smooth muscle cells. Evidence supporting the existence of a receptor for adenosine on the smooth muscle surface was obtained by (1) producing coronary vasodilation with the adenosine derivative and blocking this response with theophylline, and (2) blocking the coronary vasodilation produced by adenosine by means of the theophylline derivative.
Methods
All chemicals and reagents were purchased from either Aldrich or Sigma; Sephadex G-10 was obtained from Pharmacia.
The preparation of the compounds used in this study is summarized in Figure 1 . The synthesis of 3-(9-/?-Dribofuranosylpurin-6-yl)-3'-iminobis(propylamine) was accomplished by refluxing a magnetically stirred solution of 0.67 g of 98% 3,3'-iminobis(propylamine) in 30 ml of absolute ethanol during the portionwise addition of 1.43 g (5 mmol) of 6-chloropurine riboside. Reflux was continued for 2 hours after the last addition, the solution was diluted with 60 ml of hot absolute ethanol and was filtered rapidly through a heated BUchner funnel. The filtrate was concentrated in vacuo to approximately 10 ml, diluted with an equal volume of water, and refrigerated overnight. The product was filtered off, washed with a small amount of cold ethanol, and dried. This yielded 0.9 g (43%) of tiny white needles which begin to decompose at 115°C and to melt with decomposition at about 150°C. An additional crop of crystals of sufficient purity to use as a synthetic intermediate was obtained by concentrating the mother liquors; overall yield = 67%.
Elemental analysis for the monohydrochloride (mol wt = 417.9): The ultraviolet (UV) spectrum revealed a maximum at 270 nm, molar extinction coefficient (t) = 16.3 x 10 3 . The product migrated as a single spot on thin layer chromatogram (TLC) [diethylaminoethyl (DEAE)-cellulose developed in 100 mM tris(hydroxymethyl)aminomethane (Tris) HC1, pH 7.4, retardation factor (R r ) = 0.75; silica gel developed in 1% HC1 in absolute methanol, R r = 0.83]. The method of Lespagnol et al." was used to synthesize 8-(2-aminoethylamino)theophylline (compound II) and that of Jones and Robins 9 was followed in the synthesis of 8-diazotheophylline (compound IIJ).
The galactose residues of stachyose [O-a-galactopyranosyl-(l -6)-O-a-D-galactopyranosyl-(l -6)-O-a-D-glucopyranosyl-(l -2)-/9-D-fructofuranose] (trivial name, digalactosyl sucrose) were selectively oxidized by treating a solution containing 0.1 -1 mmol of stachyose at pH 5 with 5 mmol of NaIO 4 /mmol of stachyose. The concentrations of sugar and periodate solutions were adjusted so that the final concentration of either reactant did not exceed 0.05 M. The reaction mixture was incubated at room temperature in the dark until 80% of the periodate had been consumed, as estimated by the decrease in A J13 of 5-^1 samples diluted in 3.00 ml of water. Generally, this took 2-3 hours. The remaining periodate was destroyed by adding 50 ii\ of ethylene glycol, and the reaction mixture was passed through a column (0.75 x 5 cm) of Dowex 1 x 8 (chloride). The column was washed with 10 ml of water and the eluate and washings were used immediately in the next step. The tetra-aldehyde resulting from periodate oxidation was mixed with 5 equivalents of either compound I or II or with 3,3'-iminobis(propylamine), and the pH of the solution was adjusted to 9.5 with NaOH. After stirring at room temperature for 2 hours, the Schiff base was reduced by adding 200 mg (5.4 mmol) of NaBH 4 and stirring overnight. Excess borohydride was decomposed by lowering the pH to 5 with acetic acid and stirring for 2 hours. The pH was adjusted to 7 and the mixture was evaporated in vacuo. Several coevaporations with methanol removed most of the borate, after which the reaction mixture was dissolved in a minimum volume of water and was chromatographed on a column (2.2 x 50 cm) of Sephadex G-10 using water as the eluant. The product of the reaction of oxidized stachyose with compound II was poorly soluble at neutral pH, therefore it was dissolved in water adjusted to pH 9.5 with triethylamine; this solution also was used to equilibrate and elute the column. The initial chromatography yielded 4-5 UV absorbing peaks. The desired product, which emerged with the void volume in each case, was lyophilized and rechromatographed twice to give material consisting of a single peak. The elution profile of the reaction of oxidized stachyose and iminobis(propylamine) was determined by assay for carbohydrate using the phenol-sulfuric acid method, 10 and by spotting a sample of each fraction on paper and testing for amino groups with a ninhydrin spray reagent. These compounds are designated by the following acronyms in this communication: stachyose-iminobis(propylamino)purine riboside, STADO; stachyose-aminoethylaminotheophylline, STATHE; stachyose-iminobis(propyl)triazenotheophylline, STANTHE: and stachyose-iminobis(propylamine), STA-IBP.
Theophylline was linked covalently to STA-IBP by adding a 10-fold excess of 8-diazotheophylline to a solution of STA-IBP and adjusting the pH to 7 with 1 N NaOH. A dark brown granular precipitate was removed by centrifugation and the pale, greenish yellow product eluting as a peak with the void volume was collected, lyophilized, and purified by chromatography twice more on a column of Sephadex G-10.
The degree of substitution of the various ligands was estimated by hydrolyzing a sample of a solution of the stachyose derivative in 0.1 N HC1 at 85°C for 2 hours, neutralizing the solution, and assaying it for glucose enzymatically (Worthington glucose oxidase kit). The moles of purine in the solution, estimated spectrophotometrically using published values for molar absorbances, was divided by moles of glucose found to give the number of purine residues per mole of stachyose.
Human erythrocytes served as a model to test the ability of STADO and STATHE to penetrate cell membranes. Blood collected in heparin was ccntrifuged, the buffy coat was removed, and the cells were washed repeatedly with saline and finally suspended in saline to give a 43% hematocrit. Solutions of approximately 1 mM STADO and STATHE in 0.25 M sucrose were prepared, and 0.1-ml samples were added to quadruplicate 2-ml samples of the cell suspension, mixed by inverting the tube several times, and were incubated at 37°C for 1 hour with occasional swirling. The cells were separated by centrifugation and duplicate 0.05-ml samples of the supernatant fluid were assayed for sucrose by the phenol-sulfuric acid method. 10 A 0.5-ml samples was added to 2.00 ml of water and the absorbance at either 270 nm (STADO) or 290 nm (STATHE) was measured using a similarly diluted sample of the supernatant fluid of an untreated cell suspension as a blank. The ratio of purine absorbance to the absorbance at 480 nm in the sucrose assay from the same cell suspension was compared to that of duplicate assays on two samples containing 0.1 ml of the test solution diluted with 1 ml of water. The distribution of adenosine and theophylline in erythrocyte suspensions was not studied, since the ability of these purines to penetrate cells is well known."- 7 The coronary vasoactivity of these compounds was examined in six pentobarbital-anesthetized, open-chest mongrel dogs and in two conscious postoperative dogs.* The left coronary artery of the open-chest dogs was perfused from the left carotid artery via a Gregg cannula. An electromagnetic flowmeter interposed in the perfusion line and a Statham P23Gb manometer connected to the perfusion line via a side arm served for monitoring coronary flow and perfusion pressure, respectively. Prior to coronary cannulation each dog received 2 mg of heparin/kg intravenously, and this was augmented with an additional I mg/kg every 30 minutes thereafter. Arterial blood gas measurements guided adjustment of the respiratory minute volume and the addition of supplemental oxygen to the inspired gas to maintain pH at 7.4, Pco, between 35 and 45 mm Hg, and Po, above 90 mm Hg. The two conscious dogs were trained to lie quietly on the table without restraint, and had undergone thoracotomy 2-4 weeks previously, at which time an electromagnetic flowmeter, a pneumatic occlusive cuff, and a fine Silastic catheter had been implanted on the left circumflex coronary artery. A Silastic catheter in the aortic arch was implanted for blood pressure measurement. At the time of these studies both dogs appeared healthy and had heart rates of 50-70/min and pronounced sinus arrhythmia.
In the open-chest dogs control records included mean coronary flow and aortic pressure and the reactive hyperemic response to two 15-second coronary occlusions 10 minutes apart. Adenosine then was infused intracoronary at six rates giving adenosine concentrations in coronary plasma water ranging from 1.2 to 77.2 fiM. Each infusion was continued until coronary flow and blood pressure were stable for 30-60 seconds, and then the pump speed was increased to the next clutch setting. STADO was infused intracoronary in four of the dogs, and the effect of STANTHE on the adenosine dose-response curve was tested in five of the dogs by infusing this antagonist for 3-36 minutes, depending on the protocol, then repeating the series of adenosine infusions 2-7 minutes after discontinuing STANTHE.
The conscious dogs were studied as they lay quietly on their right side on a padded table. A typical experimental run consisted of control recordings of phasic coronary flow and aortic pressure and reactive hyperemia responses, followed by intracoronary infusions of the compound being tested from a Harvard infusion pump and a calibrated syringe at stepwise increments in rate over a 50-to 100-fold range. Each infusion was continued for 3-5 minutes, and then a record of phasic blood pressure and flow, including a short coronary flow zero, was obtained. The pump rate was advanced to the next clutch setting and this process was repeated. The experiments in the first dog compared the coronary hemodynamic effects of STADO infusions before and 9 minutes after the systemic administration of 125 mg of aminophylline. The experiments in the second dog compared the hemodynamic effects of STADO to those of adenosine both before and during a continuous infusion of theophylline and also compared the coronary vasoactivity of adenosine before and during a continuous infusion of STATHE.
Coronary conductance, calculated as the ratio of mean coronary flow to mean aortic pressure, was used as an index of coronary vascular tone in the open-chest dog experiments. In the two conscious dogs late diastolic coronary conductance was calculated as the quotient of instantaneous coronary flow rate and aortic blood pressure measured at a point in time immediately prior to the "cove" in the coronary flow tracing which is associated with atrial systole. All the complexes (generally 14-20) in a recording run were analyzed. The average values for coronary flow rate used to calculate drug concentrations were read directly from simultaneously recorded tracings of electronically meaned signals.
Changes in coronary vascular tone from control were expressed as a percentage of the difference between control conductance and conductance at maximum coronary vasodilation, induced either by 15-30 seconds of coronary occlusion or by adenosine infusions at high rates. The concentration of each compound in coronary plasma water was calculated by a formula used previously." The concentrations of the stachyose derivatives were calculated on the assumption that even though each molecule might contain more than one purine moiety, only one could interact with the putative adenosine receptor, i.e., concentration is expressed in terms of stachyose rather than purine. When appropriate, these data were plotted on semilogarithmic graph paper and the ED 50 (the concentration of agonist giving 50% of the maximum response) was estimated by interpolation. Molar potency ratios compared the effectiveness of an agonist to that of adenosine. These were calculated as the ED 60 of adenosine divided by the ED 50 of agonist.
Results
The synthesis of STADO from 0.5 mmol of stachyose yielded 0.48 g of product containing an average of 3.0 purine residues per molecule. The reaction of 150 mg of 8-diazotheophylline with 100 mg of STA-IBP (average degree of substitution = 3.3) gave 130 mg of STANTHE containing an average of 2.4 theophylline residues per molecule. The condensation of 238 mg of compound II with the oxidation product of 185 mg of stachyose yielded 310 mg of STAN-THE having an average of 3.1 theophylline residues per molecule. The UV spectra of these compounds are shown in Figure 2 . STA-IBP does not absorb light at or above 260 nm. The A max of STADO is 270 nm, as would be expected for a 6-alkylaminopurine, whereas that of STATHE, 290 nm, is 10 nm longer than that of theophylline. The spectrum of STANTHE in 0.1 N HCI has maxima at 260 and 350 nm and (not shown) at 245, 290, and 345 in 0.1 N NaOH. These spectra are characteristic of 8-alkyltriazenotheophyllines 12 and are unlike those of the starting material, 8-diazotheophylline, which has maxima in HCI at 241, 287, and 377 nm and in NaOH at 234 and 340 nm. 9 The ratio of A, 70 to A 4S0 in the supernatant fluid of erythrocytes to which STADO had been added was 1.79 ± 0.01, whereas the corresponding value in the aqueous solution was 1.78 ± 0.00. The corresponding values for the experiment with STATHE were 0.917 ± 0.005 and 0.920 ± 0.010, indicating that neither STADO nor STATHE penetrates this model cell membrane.
Intracoronary infusions of STADO regularly produced dose-dependent increases in coronary conductance in each of the five open-chest dogs to which it was given (Table I) . Maximum coronary vasodilation, i.e., equal to that attained at the peak of reactive hyperemia, was achieved in three of the four experiments. The slopes of the dose-response curves for STADO paralleled those of adenosine. The coronary vasodilation produced by STADO was more persistent than that produced by adenosine. The "t H off," i.e., the time required for coronary conductance to 50% of the way toward control, averaged 23 seconds after adenosine infusions and 74 seconds after STADO infusions. As indicated in Table 1 , STADO was less potent on a mole-for-mole basis than adenosine, the average molar potency ratio being 0.39.
Intracoronary infusions of STANTHE regularly reduced the coronary flow response to an infusion of adenosine. In these five experiments the ED 50 of adenosine was increased significantly by infusing STANTHE. The duration of adenosine vasoactivity was assessed by means of the "t^ o f f estimate in three experiments, and averaged 30 seconds.
As in the open-chest dogs, STADO caused dose-dependent coronary vasodilation when administered intracoronary in conscious dogs. Figure 3 shows the results of a typical experiment. At the highest infusion rate in this experiment STADO caused maximum coronary vasodilation, increasing late diastolic coronary conductance from a control value of 0.65 ± 0.05 ml/min per mm Hg to 5.70 ml/min per mm Hg, an increase of 877%. The ED S0 of STADO estimated from studies of this sort made on two separate days in each of the two dogs averaged 5.5 ^M, giving a molar potency ratio with respect to adenosine of 0.43. As Figure 3 shows, theophylline antagonizes the coronary effects of STADO. Immediately after the STADO infusion was finished and coronary flow had returned to control levels, theophylline was infused intracoronary at a rate of 10.3 jimol/min, a rate found in preliminary experiments to reduce the coronary flow response to adenosine by 70% but without itself causing a change in coronary hemodynamics. The estimated ED, 0 of STADO in4hi&experiment was about 4.5 ^M, but during th& theophylline infusion a similar concentration of STADO increased coronary conductance by only 8% of maximum. The effects of theophylline antagonism are reversible, however, a normal response to STADO being elicited 15 minutes after stopping the theophylline infusion. Similar STADO dose-response curves were obtained in the first dog, and infusions of STADO after the hemodynamic response to the systemic administration of aminophylline had abated elicited a rise in coronary conductance which was only 60% of control. Intracoronary infusions of STATHE giving plasma concentrations between 11.7 and 1170 ^M did not change blood pressure, heart rate, or coronary flow. However, as shown in Figure 4 , an intracoronary infusion of STATHE strongly inhibited the coronary vasodilatory effects of adenosine. Maximum coronary vasodilation was observed during an adenosine infusion which gave a concentration of 5.38 ^M in coronary plasma water. During the STATHE infusion an infusion of adenosine giving a concentration of 9.16 ^M in coronary plasma water increased coronary conductance to only 16% of maximum. The effect of STATHE was reversible, normal coronary responsiveness to adenosine being present 15 minutes after the infusion of this antagonist was discontinued.
Discussion
These experiments show that adenosine and theophylline derivatives which are too large to penetrate cell membranes are able to mimic, respectively, the coronary vasodilatory effect of adenosine and the antagonism of this effect by methylxanthines. This is evidence that both adenosine and methylxanthines exert their effects on the surface of the coronary smooth muscle cell. A similar conclusion was reached by Blinger et al.," who found that single intracoronary injections of ATP and ADP produce coronary flow increases which are earlier in onset and of greater magnitude than that of adenosine. They interpreted this faster response as indicating that these nucleotides need not be dephosphorylated in order to cause coronary vasodilation, and, because normal cells are impermeable to these nucleotides, that they act at or near the cell membrane. They also found that theophylline competitively antagonizes the coronary relaxation produced by adenosine and its various nucleotides, and also that produced by dipyridamole and papaverine.
The potency of STADO relative to that of adenosine is higher than that of other 6-alkylaminopurine ribosides, which have molar potency ratios on the order of 0.06." This could be due to the fact that these ribosides arc taken up by cells whereas STADO is not, so that the effective concentration of STADO in the vicinity of the coronary resistance vessels is probably higher, relative to its plasma concentration, than that of the ribosides.
Although this study shows that adenosine and theophylline act at the coronary smooth muscle cell membrane, the evidence that they do so via a specific adenosine receptor still is incomplete. The available evidence favoring this hypothesis is: (1) The coronary vasoactivity of adenosine analogues constitutes a congeneric series varying in potency from nil to greater than that of adenosine itself. 3 -" (2) Adenosine vasodilation is competitively inhibited by theophylline," though this does not necessarily mean that the two purines compete for the same receptor. It is possible that the interaction of adenosine with its putative receptor initiates a train of events and that the methylxanthines competitively inhibit at some succeeding step along this chain. This point probably will require additional evidence, such as chemical isolation of the receptor, adenosine-binding studies, and the demonstration that methylxanthines specifically displace bound adenosine. Even more definitive proofs, such as functional reconstruction of the receptor in a membrane system," must await the elucidation of the events which occur when adenosine interacts with the coronary smooth muscle membrane.
At this time almost nothing is known about these chemical or physical events initiated by adenosine in the 100 - coronary smooth muscle cell. The coronary relaxation produced by /9-adrenergic agonists or by drugs which are cyclic AMP phosphodiesterase inhibitors, e.g., dipyridamole, papaverine, is associated with increases in vascular cyclic AMP content. ' *• 17 However, the limited experimental evidence available does not support a role for cyclic AMP in adenosine-induced coronary relaxation," and other possible mechanisms apparently have not been examined. The method devised for the synthesis of these purine derivatives should be generally applicable to the synthesis of soluble derivatives of, for example, certain hormones and biogenic amines, which could be useful in studies of other types of cell surface receptors. This approach already has been used with ligands attached to insoluble supports such as Sepharose" and glass" beads, and to water-soluble macromolecules such as dextran. 11 As a "carrier" for ligands, stachyose has several desirable features: (1) It is a nonreducing sugar and therefore not subject to nonspecific degradation during periodate oxidation. (2) The galactose residues, by virtue of their cu-glycol configuration, are rapidly and selectively oxidized by periodate. (3) The degree of derivatization is high, potentially 4 molecules of ligand per molecule of stachyose. (4) The part of the stachyose molecule which is not affected by periodate oxidation, the sucrose moiety, is itself too large to penetrate cell membranes, and this likelihood is further diminished by the subsequent attachment of ligands. (5) The products are water-soluble, so that they can be administered to intact animals by intravascular infusion without causing vascular obstruction. (6) Though too large to penetrate cells, these derivatives are small enough to enter the interstitial space readily. (7) The likelihood that the oligosaccharide "carrier" will hinder interaction of the ligand with a membrane receptor sterically, as has been the case with Sephadex beads used in affinity chromatography," is lessened by the small size of the "carrier" and the fact that oxidation of the two galactose residues produces an extended mixed polyether,, which itself may act as a "spacer."
